new glp 1 gip drug GLP-1 V2 Capsules Sample collection:Walk-in clinic GLP-1 RA prescription trends:

new glp 1 gip drug GLP-1 V2 Capsules Sample collection:Walk-in clinic GLP-1 RA prescription trends:

GLP-1 RA prescription trends: January 2019 – December 2025 | Truveta

Providers should use the opportunity of GLP-1 receptor agonist switching to re-educate patients about the mechanisms of action and set patient expectations, especially with respect to the effects of delayed gastric emptying

Capsules

Sample collection:Walk-in clinic

Aardvark Therapeutics Sector: Oral gut-restricted bitter taste receptor agonists for hunger suppression HQ: San Diego, CA Year Founded: 2017 Origin Story: Aardvark Therapeutics was founded around a mechanistically distinct hypothesis: rather than suppressing appetite like GLP-1 drugs, the company’s lead compound activates bitter taste receptors (TAS2Rs) confined to the gastrointestinal tract to trigger local release of satiety hormones, targeting hunger itself without systemic drug exposure